ClinicalTrials.gg
CompletedNCT06053320Updated Oct 28, 2026

Spatial-Motor Stroke-Rehab Study

An interventional study of Prism adaptation therapy (PAT) + Electrical stimulation (E-stim) and Prism adaptation therapy (PAT) + Sham Stimulator in Spatial Neglect and Stroke, sponsored by Emory University. Completed at 3 sites in United States. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Emory University · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Apr 2023, registered Sep 2023).
Updated Oct 28, 2026Now CompletedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Stroke by Emory University — 4 open to participants now, 4 under way, none of them phase 3. Stroke · Emory University.

Enrollment
8th of 23
48 · median 32
Started
2023
the only one that year
No phase
17 of 23
4 open now
Registered
19th of 23
by date

Among the 23 studies in Stroke by Emory University, this one is the 8th largest by enrollment, is the only one that started in 2023, is one of 17 with no phase, and was the 19th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

4 of the 23 studies in Stroke by Emory University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Stroke by Emory University, or all of them as a file.
02

Study summary

The purpose of this study is to understand how prism adaptation training with and without electrical stimulation changes visuospatial behavior, motor system neurophysiology, and walking dysfunction.

Read the detailed description

Spatial Neglect (SN) is defined as pathological asymmetric spatial behavior causing functional disability and occurs in greater than 50% of individuals with right hemisphere stroke. SN post-stroke is associated with increased fall risk, increased hospital length of stay, poorer rehabilitation outcomes, and severe long-term disability. Prism adaptation therapy (PAT) is an evidence-based treatment for SN after stroke, however, the effects of SN on gait are not well known. Neuromuscular electrical stimulation delivered via surface electrodes is a common therapeutic adjunct in stroke rehabilitation, including for SN and gait training. However, the additive therapeutic effects of combining electrical stimulation and PAT, as well as the effects of motor training on gait deficits associated with SN are poorly understood. Furthermore, although there is limited literature examining the effects of electrical stimulation on corticospinal tract output (CST), there is an inadequate understanding of the neural mechanisms of PAT and the combinatorial effects of PAT with electrical stimulation. To parse out the neural mechanisms of PAT and electrical stimulation on the visuospatial system, researchers will first examine the effects of PAT with or without electrical stimulation in neurologically unimpaired adults, researchers will then compare results to individuals with stroke with spatial neglect.

The primary objective is to study the effects of PAT on visuospatial behavior and motor cortical excitability in able-bodied individuals (young and older), and on spatial neglect, motor cortical neurophysiology, and walking function in individuals post-stroke.

The long-term goal of this project is to develop novel, effective, and personalized rehabilitation protocols targeting SN deficits and gait dysfunction to reduce disability in stroke survivors. The rationale of this project is to explore and generate data regarding future novel combinatorial motor-spatial retraining approaches that will enhance the rehabilitation approach of SN and gait performance in individuals post-stroke.

03

Conditions studied

  • Spatial Neglect
  • Stroke

Browse trials for

Keywords

  • Post-stroke
  • Prism Adaptation Therapy (PAT)
  • Walking
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Young Adults Able Bodied (YAB) Individuals

  • 18-30 years
  • Able-Bodied (healthy without any physical disability or neurological disorder)

Older Adults Able-Bodied Individuals (OAB)

  • 45-90 years
  • Able-Bodied (healthy without any physical disability or neurological disorder)

Individuals with right hemisphere stroke (40-90 years)

  • >3 months following stroke.
  • Presence of Aiming SN
  • Ability to walk >10m with or without assistive devices.
  • Unilateral left-sided hemiparesis with gross arm strength of ≤ grade 4/5 on the Medical Research Council Scale
  • Ability to follow 3-stage commands and provide .

Exclusion criteria

Exclusion Criteria:

Young Adults Able-Bodied (YAB) Individuals and Older Adults Able-Bodied Individuals (OAB)

  • History or evidence of orthopedic or physical disability
  • History or evidence of neurological pathology
  • Pregnancy (female)
  • Uncontrolled hypertension
  • Cardiac pacemaker or other implanted electronic system
  • Presence of skin conditions preventing the electrical stimulation setup
  • Impaired sensation in the left upper limb.
  • Bruises or cuts at the stimulation electrode placement site
  • Concurrent enrollment in rehabilitation or another study.
  • History or evidence of orthopedic or physical disability interfering with study procedures
  • History or evidence of neurological pathology or disorder
  • Severe uncontrolled medical problems (e.g., hypertension, cardiovascular disease, rheumatoid arthritis, active cancer or renal disease, epilepsy) that may interfere with study procedures
  • to TMS, such as metal implants, medications that can increase cortical excitability, and unexplained dizziness in the past 6 months

Individuals with right hemisphere stroke (40-90 years)

  • History or brainstem strokes
  • Cerebellar disorders
  • Impaired sensation in the left upper limb.
  • History of other neurological disorders
  • Uncontrolled hypertension
  • Cardiac pacemaker or other implanted electronic system
  • Pregnancy (female)
  • Presence of skin condition
  • Bruises at the electrode placement site
  • Severe uncontrolled medical problems (e.g., hypertension, cardiovascular disease, rheumatoid arthritis, active cancer or renal disease, epilepsy) or other medical conditions that can interfere with study procedures
  • Contraindications to TMS, such as metal implants in the brain, medications that will increase cortical excitability, etc.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Care provider)
Enrollment
48 participants (actual)

Study arms

  • Active comparator
    Young Able-Bodied individuals

    18-30 years old able-bodied individuals (healthy without any physical disability or neurological disorder).

    Device: Prism adaptation therapy (PAT) + Electrical stimulation (E-stim) · Device: Prism adaptation therapy (PAT) + Sham Stimulator

  • Active comparator
    Old Able-Bodied individuals

    45-90 years old able-bodied individuals (healthy without any physical disability or neurological disorder).

    Device: Prism adaptation therapy (PAT) + Electrical stimulation (E-stim) · Device: Prism adaptation therapy (PAT) + Sham Stimulator

  • Experimental
    Stroke with Spatial Neglect (SN) individuals

    40-90 years individuals with more than 3 months following right hemisphere stroke.

    Device: Prism adaptation therapy (PAT) + Electrical stimulation (E-stim) · Device: Prism adaptation therapy (PAT) + Sham Stimulator · Other: Gait Training

Interventions

  • DevicePrism adaptation therapy (PAT) + Electrical stimulation (E-stim)

    PAT requires one to wear prism lenses while making arm-reaching movements toward visual targets. For treating left-sided neglect, a person wears the prism lenses that shift the visual field, including the images of the target and of one's own reaching arm, certain degrees to the right depending on the diopter of the lens (e.g., the 20-diopter lens shifts the visual field by 11.4 degrees). The visual system adapts over the repetitive practice of the arm reaching toward the target. The person eventually achieves success with a leftward movement reaching the actual target. Electrical stimulation (E-stim) involves parameters and settings commonly used in clinical practice as well as research for pain relief and other applications, commonly referred to as transcutaneous electrical nerve stimulation (TENS). TENS and E-stim are delivered using FDA-approved, commercially available portable clinical transcutaneous electrical stimulators (e.g. Empi TENS Unit).

    Also known as: PAT + E-stim

  • DevicePrism adaptation therapy (PAT) + Sham Stimulator

    Participants in the PAT with sham stim condition group will receive sham electrical stimulation treatment (electrodes will be attached but the stimulator will not be turned on) to the left upper limb with the same placement of electrodes while undergoing PAT.

    Also known as: Sham Stim

  • OtherGait Training

    After PAT, participants will complete multiple 30-seconds to 4-minute bouts of walking on the treadmill or overground at speeds ranging from self-selected to fast speeds (faster than comfortable self-selected speed), with rest breaks between bouts.

    Also known as: Gait Training After PAT

06

What researchers measure

Primary outcomes

  1. Change in visuospatial pointing behavior

    Measured by the neuropsychological laboratory pointing behavior with the Kessler Foundation Neglect Assessment Process (KF-NAP) tool. Patients are asked to point with their eyes closed towards the center (proprioceptive pointing) and eyes open towards a target (visuo-proprioceptive pointing) on a standing calibrated board unaffected hand). The test is scored by measuring the deviation from 0 (midline). Pre-PAT and post-PAT measures are compared, there is no minimum or maximum score. A more negative score (Pre to Post) means improvement in visuospatial alignment (Improved left spatial neglect) in people post-stroke.

    Time frame: Pre-training and immediately after training session

  2. Change in intracortical excitability [paired pulse transcranial Magnetic Stimulation (TMS)]

    Primary Motor Cortex (M1) and TMS from the hand muscles (first dorsal interossei) and the ankle (soleus) will be measured using Computer software (Biopac) that will record the muscle's responses to TMS pulses (MEPs) through electromyography (EMG) sensors attached to the skin of the legs and/or arms.

    Time frame: Pre-training and immediately after training session

  3. Change in corticospinal excitability (single pulse TMS)

    Change in corticospinal excitability measured by the change from baseline in motor evoked potentials (MEP) amplitude responses from the hand muscles (first dorsal interossei) and the ankle (soleus) will be measured using Computer software (Biopac) that will record the muscle's responses to TMS pulses (MEPs) through electromyography (EMG) sensors attached to the skin of the legs and/or arms.

    Time frame: Pre-training and immediately after training session

Secondary outcomes

  1. Change in spatial neglect deficits

    Measured by the clinical tests Behavioral Inattention Test (BIT). The BIT Conventional (BITC) subtest consists of 6 items: line crossing, letter cancelation, star cancellation, figure and shape copying, line bisection, and representational drawing. The Cut-offs score for the BITC is 129 out of 146. Higher scores are indicative of more severe visual impairment.

    Time frame: Pre-training and immediately after training session

  2. Change in computerized line bisection task

    Participants are asked to perform the conventional 24cm line bisection task on a 14-inch screen computer screen, placed 55cm from a seated position, with the unaffected hand using a mouse. There are 64 lines, half of which are in normal condition and half in reversed condition. The test is scored by measuring the deviation of the bisection from the true center of the line. A deviation negative of zero (0) is indicative of spatial neglect; Pre-PAT and post-PAT measures are compared, and a negative score reflects a shift to the left visual space- the effect of PAT

    Time frame: Pre-training and immediately after training session

  3. Change in the Catherine Bergego Scale (CBS)

    Measured by a validated assessment tool that is sensitive to SN and its functional sequela; CBS motor items have been validated to identify Aiming SN. The CBS uses a 4-point rating scale to indicate the severity of neglect for each item: 0 = no neglect 1. = mild neglect (patient always explores the right hemispace first and slowly or hesitantly explores the left side) 2. = moderate neglect (patient demonstrates constant and clear left-sided omissions or collisions) 3. = severe neglect (patient is only able to explore the right hemispace) This results in a total score of 30. Reported arbitrary ratings of neglect severity according to total scores: 0 = No behavioral neglect 1-10 = Mild behavioral neglect 11-20 = Moderate behavioral neglect 21-30 = Severe behavioral neglect

    Time frame: Pre-training and immediately after training session

  4. Change in weight-bearing asymmetry

    This outcome will be measured only in participants who have had a stroke. Force platform data obtained from a dual-belt instrumented treadmill during 3-d motion capture will be used to calculate inter-limb asymmetry in vertical ground reaction forces in standing and during the stance phase of gait.

    Time frame: Pre-training and immediately after training session

07

Study locations

3 sites
  • Emory Rehabilitation Hospital
    Atlanta, Georgia 30322, United States
  • Emory University Hospital (EUH)
    Atlanta, Georgia 30322, United States
  • Executive Park
    Atlanta, Georgia 30329, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The research team will share sex, age, race, and summary statistics for the results of the study (primary and secondary outcomes)

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be available from April 1, 2025 to September 1, 2025

Access criteria: Data will be shared by request by principal investigators (PIs) for data analysis to address ancillary research questions. Data will be available in data repositories e.g. DANDI.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in May 2026, 37 months.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's 37 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Sep 2026 → May 2026 and completion Sep 2026 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2023
First posted
Sep 25, 2023
StartActual
Apr 11, 2023
Primary completionActual
May 28, 2026was Sep 2026
CompletionActual
May 28, 2026was Sep 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 28, 2026
Primary completion
Sep 2026→May 28, 2026 (actual)
Oct 28, 2026
Study completion
Sep 2026→May 28, 2026 (actual)
Oct 28, 2026
Enrollment
65 (estimated)→48 (actual)
Oct 28, 2026
Documents
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Recruiting→Completed
    Documents Informed consent form ↗ posted
    Primary completion Sep 2026→May 28, 2026 (now actual)
    Study completion Sep 2026→May 28, 2026 (now actual)
    Enrollment 65 (estimated)→48 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06053320
Lead sponsor
Emory University
Responsible party
Trisha Kesar (Associate Professor, Emory University) — Principal investigator
First posted
Sep 25, 2023
Start date
Apr 11, 2023
Primary completion
May 28, 2026
Completion
May 28, 2026
Last update
Oct 28, 2026

Study contacts

Trisha Kesar, PT, PhD
principal investigator · Emory University
Fisayo Aloba, PT, DPT
principal investigator · Emory University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion